Skip to main content

Table 2 Surgery and neoadjuvant chemotherapy

From: Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Characteristic ER-Positive ER-Negative
Age<35 35≤Age<50 P-value Age<35 35≤Age<50 P-value
(N = 147) (N = 901) (N = 134) (N = 663)
Breast surgery    0.626    0.125
 Conserving 66 (44.9) 424 (47.1)   74 (55.2) 318 (48.0)  
 Mastectomy 81 (55.1) 477 (52.9)   60 (44.8) 345 (52.0)  
Axillary surgery    0.561    0.005
 SLNB 19 (16.4) 90 (10.0)   27 (20.1) 69 (10.4)  
 SLNB➔ALND 43 (26.0) 269 (29.9)   27 (20.1) 174 (26.2)  
 ALND 85 (56.2) 540 (59.9)   80 (59.7) 420 (63.3)  
 Unknown 0 (0.0) 2 (0.3)   0 (0.0) 0 (0.0)  
Neoadjuvant chemotherapy    0.090    0.068
 Anthracycline-based 111 (75.5) 689 (76.5)   107 (79.9) 504 (74.7)  
 Trastuzumab-containg 13 (8.8) 515 (5.7) 0.138 5 (3.7) 58 (8.7) 0.053
 Others 8 (5.4) 94 (10.4)   9 (6.7) 82 (12.1)  
 Unknown 28 (19.0) 118 (13.1)   18 (13.4) 89 (13.2)  
  1. NOTE: Data are presented as No. (%) unless otherwise specified
  2. ER estrogen receptor, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection